SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR

SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR

Idiopathic thrombocytopenic purpura is a chronic autoimmune hematological disease caused by an increased destruction of platelets and associated thrombocytopenia, for the treatment of which the imported drug romiplostim is used. Сreation of the drug biosimilar provides a reduction in the cost of the...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. N. Afanasyeva, V. B. Saparova, D. D. Karal-Ogly, E. I. Mukhametzyanova, D. V. Kurkin, A. V. Kalatanova, I. E. Makarenko, A. L. Khokhlov, I. A. Lugovik
Format:	Article
Language:	Russian
Published:	Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute 2022-10-01
Series:	Фармация и фармакология (Пятигорск)
Subjects:	romiplostim biosimilar gp40141 nplate® complement-dependent cytotoxicity drug safety studies in vivo in vitro idiopathic thrombocytopenic purpura toxicological profile thrombopoietin receptor tpo-r
Online Access:	https://www.pharmpharm.ru/jour/article/view/1165
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS
by: E. A. Pyadushkina, et al.
Published: (2016-02-01)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
by: Alessandro Pecci, et al.
Published: (2017-11-01)

Thrombopoietin Receptor Agonists: Clinical Use and Evaluation of Treatment Efficacy
by: A. G. Solodovnikov, et al.
Published: (2020-12-01)

The role of thrombopoietin receptor agonists in the management of adult primary immune thrombocytopenia: A single centre experience
by: Virijević Marijana, et al.
Published: (2022-01-01)

Correction of Thrombocytopenia before Elective Surgery / Invasive Procedures in Patients with Liver Cirrhosis (Experts’ Agreement)
by: M. V. Maevskaya, et al.
Published: (2024-08-01)

Results of long-term treatment with thrombopoietin receptor agonists of resistant primary immune thrombocytopenia
by: O. Yu. Vinogradova, et al.
Published: (2024-12-01)

Experimental Validation a Method for Assessing Neutralizing Antibodies of Romiplostim in Human Plasma
by: A. N. Afanaseva, et al.
Published: (2024-03-01)

Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2024-04-01)

Comparative efficacy and safety of rhTPO, romiplostim, and eltrombopag in the treatment of pediatric primary immune thrombocytopenia: a systematic review and network meta-analysis
by: Xiaofang Zhang, et al.
Published: (2025-06-01)

Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Management of patients with immune thrombocytopenia in the Moscow region
by: S. G. Zakharov, et al.
Published: (2022-11-01)

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia
by: Paschalis Evangelidis, et al.
Published: (2025-01-01)

Pharmacoeconomic Analysis of the Use of Thrombopoietin Receptors Agonists in Idiopathic Thrombocytopenic Purpura Therapy
by: VA Shuvaev, et al.
Published: (2017-10-01)

A multicenter mixed-methods study on the effects of intermittent fasting in patients with immune thrombocytopenia receiving thrombopoietin receptor agonists
by: Mohamed A. Yassin, et al.
Published: (2025-02-01)

Experience of 2<sup>nd</sup> line therapy with eltrombopag in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2023-09-01)

Clinical experience with romiplostim
by: G. B. Kuchma, et al.
Published: (2014-07-01)

SARS-COV-2 infection in a patient with Evans syndrome: A silent enemy or an ally?
by: Pantić Nikola, et al.
Published: (2020-01-01)

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
by: D. J. Kuter, et al.
Published: (2015-01-01)

PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE
by: Simone Baldini, et al.
Published: (2012-06-01)

Evaluation of the Efficacy of Romiplostim in Management of Chemotherapy-Induced Thrombocytopenia in Indian Patients: A Retrospective Study
by: Vikas Talreja, et al.

Urogenital haemorrhage secondary to Babesia gibsoni induced immune thrombocytopenia and its management with combination of romiplostim and prednisolone in a dog
by: Nadima Khan, et al.
Published: (2025-06-01)

Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?
by: Hanny Al-Samkari
Published: (2025-07-01)

Glucocorticosteroid-induced complications in patients with idiopathic thrombocytopenic purpura
by: S. G. Zakharov, et al.
Published: (2023-12-01)

Use of Immunosuppression, Romiplostim, and Splenectomy to Achieve Remission in a British Shorthair Cat With Primary Immune‐Mediated Thrombocytopenia
by: Josh M. Kennils, et al.
Published: (2025-07-01)

Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: a single-center retrospective study
by: Xijuan Lin, et al.
Published: (2025-12-01)

Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report
by: Kouki Hoshino, et al.
Published: (2019-04-01)

Research progress in the treatment of chronic primary immune thrombocytopenia
by: HUANG Zhouxuan, et al.
Published: (2025-04-01)

The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK
by: Nichola Cooper, et al.
Published: (2025-03-01)

Sustained response off treatment after fostamatinib in refractory immune thrombocytopenia: A series of four case reports
by: Waleed Ghanima, et al.
Published: (2025-12-01)

Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multirefractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists
by: Monica Carpenedo, et al.
Published: (2023-02-01)

Causal relationship between hepatic function indicators and thrombocytopenia risk in early-stage hepatitis B virus infection: evidence from clinical observational studies and mendelian randomization analyses
by: Tian-bin Chen, et al.
Published: (2025-05-01)

Real-world experience of hetrombopag in immune thrombocytopenia treatment: a retrospective cohort study
by: Dan Wang, et al.
Published: (2025-07-01)

Analysis of the efficacy of avatrombopag for the delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation for aplastic anemia
by: Xinhe Zhang, et al.
Published: (2025-08-01)

Guidelines of Russian Expert Council on diagnostic and therapy of patients with primary immunne thrombocytopenia
by: A. A. Maschan, et al.
Published: (2022-11-01)

Treatment of patients with refractory immune thrombocytopenia: literature review and case report
by: V. V. Ptushkin, et al.
Published: (2014-07-01)

CAUSES OF DEVELOPMENT OF ACUTE AND CHRONIC THROMBOCYTOPENIA IN CHILDREN OF IRKUTSK REGION
by: N. N. Martynovich, et al.
Published: (2018-09-01)

Correction of Thrombocytopenia with Thrombopoietin Receptor Agonists in Patients with Liver Cirrhosis Before Elective Surgery or Invasive Procedures
by: T. A. Deeva, et al.
Published: (2025-02-01)

Prevalence of Anti-Thyroid Peroxidase Antibody positivity and its Effect on Pregnancy Outcome in women with Unexplained infertility
by: Faranak Jalilvand, et al.
Published: (2023-07-01)

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

Comparison of Maternal Serum Levels of Thrombopoietin among Pregnant Women with and without Preeclampsia
by: Rusul Jabbar Tauma, et al.
Published: (2020-12-01)